Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 9/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | PRKDC | P78527 | 2/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.50 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.50 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13416320 | 0.96 | PIK3CG (0.60) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL188948 | 0.94 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL13416494 | 0.91 | PIK3CG (0.54) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL188954 | 0.91 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL13452388 | 0.90 | PIK3CG (0.53) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL188917 | 0.89 | PIK3CG (0.56) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL188263 | 0.89 | PIK3CG (0.56) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL188817 | 0.88 | PIK3CG (0.60) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL189464 | 0.88 | PIK3CD (0.60) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL3148018 | 0.88 | PIK3CD (0.59) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | claimed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | claimed |
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | claimed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | claimed |
| US-20110207712-A1 | Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use | EXELIXIS, INC. (US) | 2011-08-25 | — | — | US | claimed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | claimed |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2010-04-08 | — | — | US | claimed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | claimed |
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| US-9011863-B2 | Combinations of kinase inhibitors for the treatment of cancer | EXELIXIS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9011863-B2 | Combinations of kinase inhibitors for the treatment of cancer | EXELIXIS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8889664-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889664-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889664-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007044729-A2 | N- (3-AMINO-QUINOXALIN-2-YL) -SULFONAMIDE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | PIK3CA, PIK3CB, PIK3CG | PIK3CG 3/4885PIK3CD 4/4885PIK3CA 1/4885 |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CG 5/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20110207712-A1 | Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use | PIK3CA, PIK3CB, PIK3CG | PIK3CG 3/4885PIK3CD 4/4885PIK3CA 1/4885 |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CG 5/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CG 6/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | TP53, PHKG1, TNNI3K | PIK3CG 370/4885PIK3CD 339/4885PIK3CA 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.